Perrigo's Return To OTC Roots Restoring Investor Confidence

The OTC drug, infant and adult nutritionals, Rx generic topicals and API manufacturer's share price has been up since it re-stated is historical revenues from Tysabri multiple sclerosis treatment royalties and reported interim 2017 first-quarter results. Perrigo will "fully concentrate on growing" OTC portfolio.

Perrigo Co. PLC's return to its OTC private label roots restored investors' confidence following the end of a review of bookkeeping for an Rx royalty license it has divested and an interim report indicating its consumer health products business is back on track for growth.

"We will fully concentrate on growing our OTC portfolio. I am confident that we are on the right track," said...